(CercleFinance.com) – GSK announced on Friday that China has approved the marketing of its vaccine Cervarix against the human papillomavirus (HPV) in young girls aged 9 to 14 years.
The British pharmaceutical laboratory indicates that the green light from the Chinese regulatory agency for health products (NMPA) relates to a mode of administration in two doses.
Cervarix is indicated for the prevention of cervical cancer, cervical intraepithelial neoplasia and adenocarcinoma caused by virus types 16 and 18.
GSK points out that in 2020, some 110,000 new cases of cervical cancer were recorded in China, causing nearly 59,000 deaths.
The group also announced yesterday its intention to present 25 abstracts at the annual meeting of the American Society of Clinical Oncology (ASCO), which will be held next week.
GSK has also planned nine abstracts for the European Hematology Association (EHA) congress, which will be held on June 9 or 12.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.